Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL30035342 | 1.00 | — | — | |
| L-Lactic Acid SCHEMBL16958 | 1.00 | — | — | |
| Lactic Acid SCHEMBL5189465 | 1.00 | TP53 (1.00) | TP53TSHRSLC7A5ALDH1A1LMNA | |
| Lactic Acid SCHEMBL9066424 | 1.00 | — | — | |
| L-Lactic Acid SCHEMBL13165963 | 1.00 | — | — | |
| Lactic Acid SCHEMBL1412661 | 1.00 | TP53 (1.00) | TP53TSHRSLC7A5ALDH1A1LMNA | |
| D-Lactic Acid SCHEMBL14947 | 1.00 | — | — | |
| D-Lactic Acid SCHEMBL4371722 | 1.00 | TP53 (1.00) | TP53TSHRSLC7A5ALDH1A1LMNA | |
| Lactic Acid SCHEMBL9066423 | 1.00 | TP53 (1.00) | TP53TSHRSLC7A5ALDH1A1LMNA | |
| D-Lactic Acid SCHEMBL29420521 | 1.00 | TP53 (1.00) | TP53TSHRSLC7A5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4551234-A1 | REDOX-MODULATING ORGANELLE COMPLEXES | LUCA Science Inc. (JP) | 2025-05-14 | — | — | EP | claimed |
| EP-4553065-A2 | NOVEL COMPOUNDS FOR TREATING MITOCHONDRIAL DISEASE | KHONDRION IP B.V. (NL) | 2025-05-14 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20240192126-A1 | APPARATUS AND METHOD FOR BLOOD ANALYSIS | COR HEALTH, INC. (US) | 2024-06-13 | — | — | US | claimed |
| CN-113555122-B | Predictive model of transient and persistent AKI of severe sepsis patient and construction method thereof | 中南大学湘雅二医院 | 2024-04-26 | — | — | CN | claimed |
| WO-2024049115-A1 | FOOD COMPOSITION USING ENZYMATIC DECOMPOSITION EXTRACT OF ANTLERS (HENKIV®) FOR ATHLETIC PERFORMANCE ENHANCEMENT OR RECOVERY FROM FATIGUE | 주식회사 유한건강생활 | 2024-03-07 | — | — | WO | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| CN-103843889-A | Lactobacillus beverage making method | QINGDAO HUINENGDUO AGRICULTURAL DEV CO LTD | 2014-06-11 | — | — | CN | claimed |
| US-20130011516-A1 | ANTI-LISTERIAL MIXED CULTURE AND METHOD FOR PRODUCING CHEESE | CSK FOOD ENRICHMENT B.V. | 2013-01-10 | — | — | US | claimed |
| EP-2543255-A1 | Anti-listerial mixed culture and method for producing cheese | CSK Food Enrichment B.V. (NL) | 2013-01-09 | — | — | EP | claimed |
| JP-4746541-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-1648934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTATIN ANALOGUES | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | claimed |
| CN-1989805-A | Cocktail type mosquito trapping method | ZHANG YINGGUANG (CN) | 2007-07-04 | — | — | CN | claimed |
| EP-1065144-B1 | Method for packaging mussels and similar shellfish, and thus obtained package with shellfish | ROEM VAN YERSEKE B V (NL) | 2006-08-30 | — | — | EP | claimed |
| EP-1648934-A2 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTATIN ANALOGUES | Novartis AG (CH) | 2006-04-26 | — | — | EP | claimed |
| WO-2005000893-A2 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTIN ANALOGUES | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| EP-1065144-A1 | Method for packaging mussels and similar shellfish, and thus obtained package with shellfish | Roem van Yerseke B.V. (NL) | 2001-01-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | TP53 3576/4885TSHR 662/4885SLC7A5 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.